Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to Ascentage Farmers 2025 Annual Results Earnings Call. At this time, all participants are in a listen-only mode. After management's prepared remarks, we will open the call for questions. As a reminder, today's call is being recorded. Thank you for joining us. I will now turn the call over to Yuli Shen, Senior Director of Investor Relations for the Safe Harbour Statement Yuli, please go ahead. Thank you, operator. Please note that today's discussion will include forward-looking statements based on our current expectations and assumptions. These statements involve risks and uncertainties, and actual results may differ materially. For full discussion of these risks, please refer to our filings and disclosures. On today's call, I am joined by Dr. Da Junyang, Chairman and CEO, who will provide an overview of recent developments and 2025 annual performance, as well as Dr. Veet Misra, CFO, who will go through the financial highlights. The presentation will then be followed by a Q&A session. During this Q&A session, the team will be joined by Dr. Yifan Zhai, Chief Medical Officer, Dr. Xiaomeng Wang, co-founder, chief scientific advisor. Dr. Qu Chao Si, head of commercial. I will now turn the call over to Dr. Yang. Thank you. Good morning. I'm Daojin Yang, chairman and CEO of the company. Today, I'm very happy to present our 2025 four-year financial results and the corporate update. I will have the following agenda, business update, R&D highlights, financial results, and Q&A session. First, on the business update, 2025 was a breakout year for Ascentage. First, we have achieved excellent total revenue, over 90% of growth, and total $82.1 million. Our year-end cash balance is about 353.2 million cash runways through 2027. I think in 2025, we are...